Merck CEO Looking for Strategic Acquisitions -- Market Talk
Dow Jones01-14
1133 ET - Merck & Co. CEO Rob Davis sees the potential for "multi tens of billions of dollars" in acquisitions, joking that his CFO "won't let me" during a talk at the JPMorgan Healthcare Conference on Monday. "I would look at it differently and say we are not limited from a balance sheet," Davis said. "It's more, where do we see strategic opportunity." His remarks come shortly after The Wall Street Journal reported that Merck is in talks to acquire Revolution Medicines in a deal valued around $30 billion. (elias.schisgall@wsj.com)
(END) Dow Jones Newswires
January 13, 2026 11:34 ET (16:34 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments